[Clinical studies on Frubienzyme in a controlled double-blind trial].
In a controlled clinical trial Frubienzym (throat lozenges with 5 mg lysozyme, 2 mg papaine and 200 I.U. bacitracin) or placebo have been given to 100 patients with pharyngitis and/or tonsillitis for 4 days. Under treatment with Frubienzym reddening, swelling, matter and mucus in the throat, coughing, swelling and pain of lymphatic ganglions and pain of swallowing vanished more quickly than under placebo. The differences were significant (p less than 0,05, p less than 0,001 or even p less than 0,001; U-test of Wilcoxon, Man and Whitney). There were no side effects which could be attributed to Frubienzym.
D000208:Acute Disease; D000328:Adult; D001414:Bacitracin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D009113:Muramidase / Q000627:therapeutic use*; D010206:Papain / Q000627:therapeutic use*; D010612:Pharyngitis / Q000188:drug therapy*; D014069:Tonsillitis / Q000188:drug therapy*
D004338:Drug Combinations; D001414:Bacitracin; D009113:Muramidase; D010206:Papain
Klinische Untersuchung von Frubienzym in einer randomisierten Doppelblind-Studie